<DOC>
	<DOCNO>NCT00539136</DOCNO>
	<brief_summary>This study conduct healthy volunteer investigate absorption GSK561679 use Gamma Scintigraphy , PillCam™ SB capsule acoustic vest .</brief_summary>
	<brief_title>A Study Examine Absorption GSK561679 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male age 1855 year , inclusive . Healthy subject , define individual free clinically significant illness disease ( include peptic ulcer disease psychiatric illness ) determine medical psychiatric history ( include family ) , physical examination , laboratory study , test . Body weight &gt; /= 50 kg ( 110 lb ) BMI within range 18.529.9 kg/m2 inclusive Demonstrates evidence active disease , physical mental impairment . Selfadministered Beck Depression Inventory II scale total score great 9 , suicide question score zero . Nonsmoker ( abstinence smoking least 6 month start study ) . Normal electrocardiogram ( subject must clinically significant abnormality 12lead ECG ) . Agree remain clinic time define protocol . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction . As result medical interview , physical examination , evaluation mental state psychiatric history screen investigation , physician responsible considers subject unfit study . History clinically significant psychiatric illness . Any history suicidal attempt behavior . Any history endocrine disorder include , limited , diabetes disorder hypothalamus , pituitary , adrenal , thyroid gland , gonadal disorder dysfunction reproductive organ . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . Current recent ( within one year ) gastrointestinal disease ; history malabsorption , oesophageal reflux , irritable bowel syndrome intestinal obstruction ; frequent ( week ) occurrence heartburn ; surgical intervention ( e.g. , cholecystectomy ) would expect influence absorption drug . History presence allergy study drug drug class , history drug allergy , opinion physician responsible , contraindicate participation . LFTs elevate &gt; 1.5 time reference range prestudy screen remain elevated repeat LFT ( discuss sponsor , necessary ) . Any clinically significant laboratory abnormality . The subject screening ECG value outside range specify protocol . A semisupine systolic blood pressure le 90 mmHg great 140 mmHg semisupine diastolic blood pressure le 60 mmHg great 90mmHg ; radial pulse rate le 40 bpm 90 bpm . A positive prestudy HIV 1 , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month start study . Subjects negative Hepatitis B , C HIV test last 3 month require repeat test . The subject positive prestudy urine drug/alcohol screen . . History regular alcohol consumption average 21 drinks/week within 6 month screen . Average daily caffeine intake equivalent &gt; 4 cup coffee &gt; 6 cup tea . Consumption grapefruit juice grapefruit within 14 day prior first dose study medication . The subject vegetarian and/or specific dietary requirement would prevent eat meal provide study . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . An unwillingness use condom/spermicide sexual intercourse pregnant lactate woman time first dose study medication five half life follow administration last dose study medication . An unwillingness use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 84 day follow administration last dose study medication . The subject receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Where participation study would result donation excess 600 mL blood within 56 day period . Radiation exposure , include present study , exceed cumulative total effective dose equivalent 10mSv last 3 year . Radiation exposure previous clinical trial include , clinical ( therapeutic diagnostic ) radiation exposure include . Radiation exposure clinical trial , include present study , diagnostic Xrays , exclude background radiation , exceed target organ ( colon ) dose 50mSv ( 5 rem ) single dose within last 30 day cumulative dose 150mSv ( 15 rem ) last twelve ( 12 ) month . No subject whose occupation require monitor radiation exposure enrol study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>GSK561679 ,</keyword>
	<keyword>Pharmacokinetic ,</keyword>
	<keyword>healthy volunteer ,</keyword>
	<keyword>Gamma Scintigraphy ,</keyword>
	<keyword>PillCam™ ,</keyword>
	<keyword>acoustic vest</keyword>
</DOC>